From: Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients
 | Hazard ratio(95% CI) | P |
---|---|---|
Univariate | Â | Â |
 hsa-miR-188-5p | 1.02(0.70 -1.48) | 0.91 |
 hsa-miR-19a | 0.85(0.35 -1.77) | 0.66 |
 hsa-miR-193a-5p | 0.60(0.35 -1.02) | 0.06 |
 hsa-miR-374b | 0.61(0.50 -0.75) | 0.000** |
 Gleason score | 3.32(2.26-4.87) | 0.000** |
 Preoperative PSA | 1.00(1.00-1.01) | 0.013* |
 Pathological tumor stage | 3.85(1.59-9.32) | 0.003** |
 Age | 1.04(0.98-1.09) | 0.19 |
 Clinical stage group | 0.85(0.39-1.89) | 0.69 |
Multivariate | Â | Â |
 hsamiR374b | 0.38(0.17 -0.85) | 0.018* |
 Gleason score | 2.39(1.34-4.23) | 0.003** |
 Preoperative PSA | 1.01(1.00-1.01) | 0.022* |
 Pathological tumor stage | 2.17(0.64-7.37) | 0.21 |